Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
898 participants
OBSERVATIONAL
2001-05-30
2030-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy
NCT06114160
Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines
NCT05193734
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
NCT01129362
First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine
NCT01188512
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants
NCT01890850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* to follow the duration of protection of the Ca vaccines in the context of modifications of the vaccine recommendations
* to describe the clinical characteristics of a population vaccinated with several boosters
* to adapt complementary examinations for diagnostic purposes (culture, PCR, serology) according to the evolution of scientific knowledge
* to monitor B. parapertussis infections
* to train laboratories with nasopharyngeal aspiration
* to monitor the evolution of the bacterial species All children aged 0-18 years, in whom the diagnosis of pertussis is mentioned and for which a biological check-up is requested, are included, except asymptomatic children with confirmed family case.
In case of suspected pertussis, real-time PCR and / or culture and / or (rarely) serology is / are still prescribed to the patient and / or his entourage.
Selected Pediatricians from the ACTIV group and the AFPA working in an outpatient clinic, located in different places in France, are participating in this network since 2001. The clinical evolution and the results of the examinations are transcribed on a case report form. The data are collected, firstly, during the visit where the diagnosis of whooping cough is suspected and a biological assessment requested (patient's medical history, clinical data, vaccination status and dates, as well as the search for a contaminated/contaminator) and secondly during the follow-up visit (results of the biological check-up and diagnosis, antibiotics potentially prescribed, and supplement data of the entourage, except in case of diagnosis of pertussis not retained).
All evaluations made by the pediatricians are regularly reviewed during meetings, and final diagnoses used are:
* biological pertussis
* epidemiological pertussis
* not evaluable
* lost of follow up
* no whooping cough
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non interventional study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* cases for which the pertussis diagnosis was not suspected by the pediatrician
1 Day
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sanofi
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Association Clinique Thérapeutique Infantile du val de Marne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicole Guiso
Role: STUDY_DIRECTOR
Institut Pasteur
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ACTIV
Créteil, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Whooping cough surveillance in France in pediatric private practice in 2006-2015
Pertussis surveillance in private pediatric practices, France, 2002-2006
Guidelines for diagnosis of whooping cough
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACT0606
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.